Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 25, 2007

Eisai to Continue Support of TorreyPines’ Alzheimer’s Target Discovery Work

  • TorreyPines Therapeutics and Eisai extended their collaboration related to discovery of Alzheimer’s targets by a year. The goal of the genetics research is to identify and validate genes associated with the disease.

    Under the terms of the agreement and in connection with the extension, TorreyPines will receive an upfront payment and continued research funding. Eisai will continue to have exclusive rights of first negotiation and refusal for gene targets discovered and validated through the research.

    The companies have a separate partnership to find compounds to treat Alzheimer’s, which was also recently extended.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »